Peripheral Arterial Disease News and Research

RSS

European Commission approves MICARDIS medication for CV protection

MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.

27 Nov 2009

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS(R) (telmisartan) has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme (ACE) inhibitor.

26 Nov 2009

UCLA engineers and physicians develop PAD treatment device to prevent thrombosis

A fortuitous discovery that grew out of a collaboration between UCLA engineers and physicians could potentially offer hope to the nearly 10 million Americans who suffer from peripheral arterial disease.

26 Nov 2009

100th patient enrolled in Atrium Medical's iCAST Atrium Registry Ultrasound Study

Atrium Medical Corporation announced that the 100th patient was enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). The iCARUS study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease in the iliac artery.

23 Nov 2009

Cardiovascular Systems commences patient enrollment in CALCIUM 360° clinical trial

Cardiovascular Systems, Inc., announces the first patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company’s 360° Clinical Series. The CALCIUM 360° study will evaluate the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI’s Diamondback 360® PAD System, a minimally invasive catheter for treating PAD anywhere in the leg.

19 Nov 2009

Report on the epidemiology of PAD, TAO and CLI in India

A new analysis published by THE SAGE GROUP concludes that atherosclerotic peripheral arterial disease (PAD) afflicts over 20 million in India. Both PAD and CLI represent major and significantly underestimated problems for the Indian economy and healthcare system.

13 Nov 2009

Resources to help understand stroke and carotid artery disease

The Society of Interventional Radiology offers numerous resources-including publications and the first-ever Catheter Lysis of Thromboembolic Stroke (CLOTS) course-for interventional radiologists, neuroradiologists, neurointerventionists, body interventionalists, and IR and INR fellows to aid in the understanding of stroke and carotid artery disease.

12 Nov 2009

Catheter-directed therapy: First-line treatment option for massive pulmonary embolism

Catheter-directed therapy or catheter-directed thrombolysis-an interventional radiology treatment that uses targeted image-guided drug delivery with specially designed catheters to dissolve dangerous blood clots in the lungs-saves lives and should be considered a first-line treatment option for massive pulmonary embolism, note researchers in the November Journal of Vascular and Interventional Radiology.

12 Nov 2009

Webinar: Latest updates on percutaneous and transcatheter treatment of liver, kidney and lung tumor ablation

Registration is now open for the Society of Interventional Radiology's "Image-guided Interventional Oncology (IO) Therapies" Webinar, which will provide the latest updates on percutaneous and transcatheter treatment of liver tumors, kidney tumor ablation and lung tumor ablation.

7 Nov 2009

Declining kidney function linked to higher risk of heart failure in individuals with or without kidney disease

Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

6 Nov 2009

Vascular surgeons are endovascularly-trained and have better safety records

Vascular surgeons have the highest market share and the lowest overall mortality and morbidity rates for peripheral arterial interventions (PAI), when compared to interventional cardiologists and interventional radiologists who also perform this procedure.

28 Oct 2009

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.

23 Oct 2009

Vasamed partners with BBHOP for peripheral arterial disease research

On Saturday, November 7, 2009 Vasamed Inc., provider of diagnostic technologies that detect peripheral arterial disease in patients with diabetes, will partner with the Black Barbershop Health Outreach Program (BBHOP) in its mission to help African Americans identify the connection between peripheral arterial disease (PAD), diabetes, obesity and hypertension through early detection and referral to appropriate medical resources.

23 Oct 2009

Peripheral arterial disease linked to lifestyle changes

Modifying the risk of peripheral arterial disease (or PAD)-with healthy lifestyle changes-remains vital to one's health, note researchers in a recent issue of the Journal of Vascular and Interventional Radiology. And while PAD can progress and worsen over time, there is not enough evidence yet to advocate minimally invasive treatment in patients who have had a narrowing or blockage of a leg artery but showing no signs or symptoms of the disease, say Irish researchers in a retrospective study of more than 900 individuals.

22 Oct 2009

Cook Medical launches new products for treating peripheral arterial disease

In a tour de force of new product development and introduction, Cook Medical is introducing six new products in parallel to provide better treatment options to the physicians treating the 27 million people worldwide* afflicted with some form of peripheral arterial disease (PAD) and other diseases of the circulatory system.

21 Oct 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

Cardiovascular Systems to build new manufacturing facility in Texas

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, has signed a 10-year lease agreement for a new 46,000-square-foot manufacturing facility in Pearland, Texas.

6 Oct 2009

Society of Interventional Radiology offers intensive five-day course

The Society of Interventional Radiology presents Catheter Lysis of Thromboembolic Stroke (CLOTS)-an intensive five-day course featuring top interventional radiologists, neurointerventionists, neurologists and neuroradiologists offering doctors the opportunity to gain and/or upgrade skills to incorporate acute ischemic stroke care into their practice.

1 Oct 2009

Scholarship fund for interventional radiology fellows

The Society of Interventional Radiology Foundation recently received a $1 million planned-gift donation to create a future scholarship fund for interventional radiology fellows to pursue this medical profession. SIR Foundation is dedicated to advancing the clinical needs of interventional radiology by specializing in developing investigators trained in conducting pivotal basic and clinical trials research.

24 Sep 2009

Pathway Medical's Jetstream G2 NXT catheter boosts its growth by 172 percent over the last two quarters

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced a 172 percent growth over the last two quarters with its Jetstream peripheral revascularization catheters at more than 150 centers of excellence in the United States.

23 Sep 2009